ZS Pharma Company Profile (NASDAQ:ZSPH)

Analyst Ratings

Consensus Ratings for ZS Pharma (NASDAQ:ZSPH) (?)
Ratings Breakdown: 5 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $92.17 (2.43% upside)

Analysts' Ratings History for ZS Pharma (NASDAQ:ZSPH)
Show:
DateFirmActionRatingPrice TargetActions
11/18/2015Citigroup Inc.DowngradeBuy -> Neutral$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015JPMorgan Chase & Co.DowngradeOverweight -> Neutral$75.00 -> $90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Morgan StanleyDowngradeOverweight -> Equal Weight$79.00 -> $90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Credit Suisse Group AGDowngradeOutperform -> Neutral$67.00 -> $90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015William BlairDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2015BMO Capital MarketsReiterated RatingBuy$70.00 -> $83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for ZS Pharma (NASDAQ:ZSPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/9/2015Q315($1.04)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015($0.90)($1.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.86)($1.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2015Q414($0.75)($0.98)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.74)($0.81)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.66)($4.72)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ZS Pharma (NASDAQ:ZSPH)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ZS Pharma (NASDAQ:ZSPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ZS Pharma (NASDAQ:ZSPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/21/2015Todd A. CreechCFOSell70,000$49.84$3,488,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Alta Partners Viii, L.P.Major ShareholderSell175,427$57.86$10,150,206.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Alta Partners Viii, L.P.Major ShareholderSell111,597$57.30$6,394,508.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Alta Partners Viii, L.P.Major ShareholderSell296,423$58.00$17,192,534.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014A/S NovoInsiderBuy275,000$18.00$4,950,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Guy P NohraDirectorBuy200,000$18.00$3,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Park Bioventures Lp DevonMajor ShareholderBuy160,000$18.00$2,880,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ZS Pharma (NASDAQ:ZSPH)
DateHeadline
07/22/16 07:14 PMWhat To Do With Your Relypsa Winnings - Seeking Alpha
07/22/16 07:14 PMHC Wainwright Weighs In On Two Healthcare Stocks: Relypsa Inc (RLYP) and Biogen Inc (BIIB) - Smarter Analyst
07/21/16 10:18 AMBid war beckons after Galenica snaps up Relypsa, brokers say - Proactive Investors USA & Canada
07/15/16 12:48 PMCrowd Rating and Earnings Recap for ZS Pharma, Inc. (NASDAQ:ZSPH) - Telanagana Press
07/14/16 11:03 AMZS Pharma, Inc. (NASDAQ:ZSPH) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 09:19 AMZS Pharma, Inc. (NASDAQ:ZSPH) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 09:19 AMTrading Performance and Target Watch for ZS Pharma, Inc. (NASDAQ:ZSPH) - Press Telegraph
07/08/16 10:15 AMWall Street Ratings and Target Price Views on ZS Pharma, Inc. (NASDAQ:ZSPH) - Telanagana Press
07/01/16 07:26 PMNew Broker Ratings For ZS Pharma, Inc. (ZSPH) - FTSE News
06/30/16 07:39 PMZS Pharma, Inc. (NASDAQ:ZSPH) Company Rating and Target Watch - Telanagana Press
06/27/16 07:11 PMZS Pharma, Inc. (NASDAQ:ZSPH) Earnings Glance and Target Price Review - Engelwood Daily
06/18/16 04:19 AMBrokers Issue Average Price Target Of 87.00 On ZS Pharma, Inc. (ZSPH) - Fiscal Standard
06/01/16 10:33 AMStock Review and Earnings Check on ZS Pharma, Inc. (NASDAQ:ZSPH) - HNN - Stock Review and Earnings Check on ZS Pharma, Inc. (NASDAQ:ZSPH)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting ZS Pharma, Inc. (NASDAQ:ZSPH) ...and more »
05/30/16 06:46 PMNext Weeks Broker Price Targets For ZS Pharma, Inc. (ZSPH) - Share Trading News - Next Weeks Broker Price Targets For ZS Pharma, Inc. (ZSPH)Share Trading NewsZS Pharma, Inc. has a 50 day moving average of 85.57 and a 200 day moving average of 66.48. It has a 52-week low of 37.52 and a 52-week high of 91.24. The share price of the company (ZSPH) was up +0.00%, with a high of 0.00 during the day and the ...and more »
05/27/16 10:42 AMShares Of Relypsa Inc. Are Surging Again -- Here's Why -
05/27/16 10:40 AMAstraZeneca's Good Deal Turns Bad -
05/27/16 06:47 AMAstraZeneca Remains Committed To Development Of ZS-9 Despite Letter From FDA -
02/26/16 09:50 AMLatest Analysts Reports On ZS Pharma, Inc. (ZSPH) - Risers & Fallers - Latest Analysts Reports On ZS Pharma, Inc. (ZSPH)Risers & FallersZS Pharma, Inc. has a 50 day moving average of 85.57 and a 200 day moving average of 66.48. It has a 52-week low of 37.52 and a 52-week high of 91.24. The share price of the company (ZSPH) was up +0.00%, with a high of 0.00 during the day and the ...ZS Pharma, Inc. (NASDAQ:ZSPH)'s Opens At 89.98Vanguard Tribuneall 2 news articles »
02/05/16 02:59 AMQuestor share tip: AstraZeneca faces Crestor crunch in year ahead -
02/02/16 12:01 PMPrice Target Update On ZS Pharma, Inc. (ZSPH) - Risers & Fallers - Price Target Update On ZS Pharma, Inc. (ZSPH)Risers & FallersA number of investment brokers have recently updated their price targets on shares of ZS Pharma, Inc. (ZSPH). Most recent broker ratings. 11/18/2015 – ZS Pharma, Inc. was downgraded to “neutral” by analysts at Citigroup. They now have a USD 82 price ...
01/29/16 11:53 AMThe Gabelli ABC Fund Merger and Arbitrage Shareholder Commentary for Q4 - The Fund earned a 3.14% annualized return. ZS Pharma Inc. (NASDAQ:ZSPH) is a pharmaceutical company based in Coppell, Texas that developed a drug to treat hyperkalemia. On November 6, 2015, AstraZeneca plc (0.3%) announced it would acquire ZS Pharma in a $ ...
01/22/16 06:06 PMZS Pharma, Inc. (NASDAQ:ZSPH) - Stock Sentiment And ABR Update - Investor Newswire - ZS Pharma, Inc. (NASDAQ:ZSPH) - Stock Sentiment And ABR UpdateInvestor NewswireZacks Research has given an average broker rating of N/A to ZS Pharma, Inc. (NASDAQ:ZSPH)'s shares. Zacks assigns a simplified score in between one and five against the complex analysts' ratings. A score towards 1-2 typically means a consensus Buy, ...and more »
01/22/16 10:58 AMZS Pharma, Inc. (ZSPH) Recent Analyst Updates - Risers & Fallers - ZS Pharma, Inc. (ZSPH) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of ZS Pharma, Inc. (ZSPH). According to the latest broker reports outstanding on Thursday 21st January, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
12/22/15 12:32 AMActelion says selexipag to enter U.S. market in January - [Reuters] - Actelion Ltd has received approval from the U.S. Food and Drug Administration to bring its pulmonary arterial hypertension drug selexipag, or Uptravi, to the market. The Swiss company said selexipag, indicated ...
12/21/15 06:08 PMAstraZeneca completes acquisition of ZS Pharma - [at noodls] - AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced ...
12/18/15 11:47 AMAstraZeneca PLC -- Moody's downgrades AstraZeneca to A3, stable outlook -
12/17/15 04:07 PMZS PHARMA, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur -
12/17/15 10:09 AMAstraZeneca buys most of Acerta for $4 billion to add cancer drug -
12/14/15 08:30 AMAstraZeneca confirms interest in a possible $5B purchase -
12/08/15 12:17 PMZS PHARMA, INC. Financials -
12/04/15 02:31 PMRelypsa Stock Jumps On Buyout Rumors -
12/02/15 02:44 PMZS Pharma Inc (ZSPH) Generating Strong Interest from Top Money Managers -
11/25/15 01:19 PMAre Hedge Funds Dumping Amicus Therapeutics, Inc. (FOLD)? -
11/20/15 10:57 AMHedge Fund Sentiment Has This to Say About These Moves on 3 Healthcare Stocks -
11/13/15 11:49 AMINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ZS Pharma, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to AstraZeneca PLC -- ZSPH - [PR Newswire] - NEW YORK, Nov. 13, 2015 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased ZS Pharma, Inc. (NASDAQGM: ZSPH) stock prior to November ...

Social

About ZS Pharma

ZS Pharma logoZS Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. The Company's zirconium silicate technology allows it to create selective ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. The Company has completed Phase III development of its product candidate, sodium zirconium cyclosilicate (ZS-9), for the treatment of hyperkalemia, a life-threatening condition in which elevated levels of potassium increase the risk of muscle dysfunction, including cardiac arrhythmias and sudden cardiac death. The Company has completed three clinical studies with ZS-9 for patients with hyperkalemia, including patients with chronic kidney disease (CKD), heart failure (HF), diabetes and those on renin-angiotensin aldosterone system (RAAS) inhibitor therapy.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZSPH
  • CUSIP:
Key Metrics:
  • Previous Close: $89.98
  • 50 Day Moving Average: $85.57
  • 200 Day Moving Average: $66.48
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-4.68 EPS
  • Next Year EPS Consensus Estimate: $-5.08 EPS
Additional Links:
ZS Pharma (NASDAQ:ZSPH) Chart for Monday, July, 25, 2016